Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China

Randomized, double-blind, placebo-controlled Phase I studies

Rong-Cheng Li Guangxi Autonomous Region Center for Disease Prevention and Control; Nanning City, Guangxi, P.R. ChinaCorrespondence[email protected]

Yan-Ping Li Guangxi Autonomous Region Center for Disease Prevention and Control; Nanning City, Guangxi, P.R. China

Zhao-Jun Mo Guangxi Autonomous Region Center for Disease Prevention and Control; Nanning City, Guangxi, P.R. China

Dong Luo Liucheng County Center for Disease Prevention and Control; Guangxi, P.R. China

Teng Huang Guangxi Autonomous Region Center for Disease Prevention and Control; Nanning City, Guangxi, P.R. China

Ji-Lian Kong Liucheng County Center for Disease Prevention and Control; Guangxi, P.R. China

Lao-Hong Wang Liucheng County Center for Disease Prevention and Control; Guangxi, P.R. China

Ning-Sheng Song Liucheng County Center for Disease Prevention and Control; Guangxi, P.R. China

Aixue Liu GlaxoSmithKline Biologicals; King of Prussia, PA USA

Helen Zhang GlaxoSmithKline Investment Co. Ltd; Beijing, P.R. China

Xueyan Liao GlaxoSmithKline Investment Co. Ltd; Beijing, P.R. China

Naveen Karkada GlaxoSmithKline Biologicals; Bangalore, India

Htay Htay Han GlaxoSmithKline Biologicals; King of Prussia, PA USA